Novartis AG vs Workday Inc — how do they compare? Novartis AG trades at $143.53 (market cap $268.57B), while Workday Inc trades at $187.03 (market cap $45.26B). The key difference: Novartis AG is far larger — about 5.9× Workday Inc's market cap, and Novartis AG pays a 3.31% dividend while Workday Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Workday Inc for 38 Days on average.
| NVS | WDAY | |
|---|---|---|
Market Cap | $268.57B | $45.26B |
Volume | 1,532,573 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $168.62 | $245.67 |
52-Week Low | $121.80 | $112.55 |
Typical Hold Time | 82 Days | 38 Days |
Enterprise Value | $309.89B | $45.63B |
Dividend Yield | 3.31% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Workday (WDAY) trades at $185.67, up 0.77% with neutral technical signals and strong fundamental momentum. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth remains robust, projected to reach $10.2B in 2026, while profitability metrics show improvement. Recent strategic moves include expansion into the UAE market and AI product launches, though layoffs and a fraud investigation present headwinds. Analyst consensus leans bullish with a $202.92 price target, suggesting 9% upside potential from current levels.
WDAY presents a compelling growth story with AI-driven revenue acceleration and expanding profit margins, but faces execution risks amid restructuring and competitive pressures. The stock's premium valuation (P/E 38.25) requires sustained high growth to justify current levels. Institutional sentiment remains positive despite near-term volatility, with the key catalyst being Q3 earnings delivery against expectations of $2.74 EPS.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →